15 / 17
Volume 3, Issue 4 (Suppl)
Nano Res Appl
ISSN: 2471-9838
November 07-08, 2017 Singapore
International Meeting on
Advanced Nanomaterials and Nanotechnology
Nanomaterials Meetings 2017
November 07-08, 2017
Page 41
Therapeutic natural lipid nano-formulation rectifies molecular parameters of critical-inflammation
pathogenesis.
Debjyoti Paul
Division of Molecular Medicine, Bose Institute, India
Background:
Nano-formulating natural biomolecules, including naturally occurring polyunsaturated fatty acid rich systems with
proven therapeutic benefits, are being viewed as elegant solutions for unlocking the untapped potential of such molecules for
translational research against critical disease pathogenesis. However, despite preliminary and at best theoretical promises, empirical
evidences to establish the higher bio-functionality of therapeutic lipids as nano-templates are starkly lacking. In this context, this work
presents encouraging real-time findings against both
in vivo
and
ex vivo
inflammation models for a therapeutic lipid, alpha-eleostearic
acid (ESA), encapsulated in a novel and thoroughly characterized bio-compatible nano-emulsion (NE) system (particle sizes less than
200 nm).
Methods:
A protocol involving high pressure homogenizer was developed to fabricate novel formulations of ESA and was characterized
with standardized methods of DLS and TEM. Molecular biological tools and assays were employed to arrive at a definite conclusion.
Results:
Among the treated experimental groups, the pro-inflammatory profile was found to be significantly mitigated in the
hypersensitized rats administered with 0.25% ESA-NE formulation. ESA NE also restored the cell cycle phases of splenocytes to
normal conditions and in a more emphatic manner as compared to ESA CE. The short-term effect of the formulations in the isolated
human PBMCs challenged with and without lipopolysaccharide (LPS) for cell-surface bio-marker (CD 14, CCR5/CD195) expressions,
also revealed novel findings.
Conclusion:
The novel ESA NE formulation shows lot of palpable promise for clinical applications against pathogenic and delayed
type-hypersensitivity.
Biography
Debjyoti Paul, is presently a post-doc in the laboratory of Sr. Professor Parimal Chandra Sen, Molecular Medicine division of the Bose Institute, Centenary Campus,
located in Kolkata. Dr. Paul did his PhD. from the University of Calcutta in nano-formulations of therapeutic conjugated linolenic acid isomer, and has provided one
of the earliest evidences of such lipids as nano-systems in ameliorating bio-molecular parameters against, diabetes, pathogenic mitogens and allergens. He has
also been a pioneer in putting forward a stable formulation system to emulsify such PUFAs for clinical applications that can be nano-sized without leading to the
formation of undesirable lipid-artifacts. His present focus is in developing nano-carriers to deliver novel drugs against mi-RNAs associated with Triple Negative
Breast Cancer Cells.
djpbiotech@gmail.comDebjyoti Paul, Nano Res Appl 2017, 3:4
DOI: 10.21767/2471-9838-C1-005